{"id":"W3143844999","doi":"10.1016/j.annonc.2021.03.205","title":"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; McGill University; University of Ottawa; Regional Municipality of Durham; Juravinski Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Jewish General Hospital; Kelowna General Hospital; CancerCare Manitoba; Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Lakeridge Health; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Terry Fox Research Institute; Movember Foundation; Prostate Cancer Foundation","keywords":"Cabazitaxel; Enzalutamide; Medicine; Abiraterone; Prostate cancer; Open label; Oncology; Docetaxel; Internal medicine; Phases of clinical research; Clinical trial; Chemotherapy; Cancer; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007034444,0.000249242,0.001069797,0.0001587236,0.0001247215,0.00004000446,0.0001840989,0.0001142837,0.0005727942],"category_scores_gemma":[0.0007175572,0.0001823784,0.00009487592,0.0005592681,0.0001884349,0.0002141525,0.0001662304,0.0002540074,0.00001015437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002514937,"about_ca_system_score_gemma":0.003943232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001034401,"about_ca_topic_score_gemma":0.004830962,"domain_scores_codex":[0.9972668,0.0004190377,0.0008497766,0.0004930622,0.0003580256,0.0006133322],"domain_scores_gemma":[0.9980627,0.0005306064,0.0003041562,0.0002456755,0.0006053086,0.0002515625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8700184,0.01426598,0.0001260236,0.0002542003,0.0009213664,0.002845904,0.001281269,0.000008229154,0.04268453,0.0000362383,0.002733927,0.06482398],"study_design_scores_gemma":[0.8736433,0.04033234,0.0001388266,0.0002495617,0.00040559,0.00002344924,0.001016403,0.0001663727,0.07434037,0.00004282654,0.009449295,0.0001916626],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773959,0.004566929,0.000001712938,0.01162875,0.0003963613,0.004904432,0.0002714726,0.00001861841,0.0008158039],"genre_scores_gemma":[0.9828112,0.007619512,0.00169224,0.0006367739,0.0001316122,0.002434168,0.0002607185,0.00004123026,0.004372586],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06463232,"threshold_uncertainty_score":0.7437175,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2852932482117954,"score_gpt":0.5082174511914536,"score_spread":0.2229242029796582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}